Welcome to our dedicated page for Ironwood news (Ticker: IRWD), a resource for investors and traders seeking the latest updates and insights on Ironwood stock.
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) is a biotechnology company focused on gastrointestinal (GI) and rare diseases, and its news flow reflects this specialization. Investors and followers of IRWD news will see regular updates on the performance and clinical development of its key assets, particularly LINZESS® (linaclotide) and apraglutide.
News about LINZESS often covers U.S. net sales, prescription demand trends based on IQVIA data, and changes in financial guidance related to collaboration revenue and adjusted EBITDA. Ironwood and its U.S. partner AbbVie share equally in U.S. brand collaboration profits, so quarterly and full-year results frequently highlight LINZESS commercial margin, net profit for the U.S. brand collaboration, and the impact of pricing dynamics, gross-to-net rebate reserves and healthcare policy changes.
For apraglutide, Ironwood’s news includes clinical and regulatory milestones in short bowel syndrome with intestinal failure (SBS-IF). Press releases describe data from the STARS Phase 3 trial and the STARS Extend long-term extension study, including the number of apraglutide-dosed patients achieving enteral autonomy, as well as feedback from the U.S. Food and Drug Administration on the need for a confirmatory Phase 3 trial. Updates on the timing and design of this confirmatory trial and on regulatory submissions are recurring themes.
IRWD news also covers financial guidance for LINZESS U.S. net sales, total revenue and adjusted EBITDA, along with restructuring activities, cost management efforts and strategic reorganization steps. Additional announcements address topics such as Nasdaq listing notifications, changes in the company’s independent registered public accounting firm, participation in investor and scientific conferences, and the ongoing review of strategic alternatives with financial advisors.
By following this IRWD news page, readers can track how Ironwood’s GI and rare disease programs progress over time, how financial expectations evolve, and how regulatory, commercial and strategic developments may influence the company’s outlook.
Summary not available.
Summary not available.
Ironwood Pharmaceuticals (Nasdaq: IRWD) has authorized a new share repurchase program allowing for the buyback of up to $150 million of its outstanding shares through December 2022. This initiative reflects Ironwood's disciplined capital allocation strategy and confidence in its financial position. The company aims to return cash to shareholders while continuing to focus on maximizing revenues from LINZESS® and developing innovative treatments for GI diseases. Management will determine the timing and method of repurchases based on market conditions.
Ironwood Pharmaceuticals (Nasdaq: IRWD) reported strong first quarter 2021 results, with total revenues of $88.8 million, up 11% from $79.9 million in Q1 2020. LINZESS prescription demand grew 12% year-over-year, contributing to net sales of $215.4 million. GAAP net income surged to $39.9 million or $0.25 per share, compared to $3.3 million or $0.02 per share last year. Operating expenses decreased significantly to $43.4 million. Ironwood ended Q1 with $438.5 million in cash and cash equivalents, positioning itself well for future investments.
Ironwood Pharmaceuticals (NASDAQ: IRWD) has announced its first quarter 2021 investor update conference call and webcast scheduled for May 6, 2021, at 8:30 a.m. Eastern Time. Interested participants can join by calling (833) 350-1432 for U.S. and Canada, or (647) 689-6932 internationally, using conference ID 8067476. A replay will be available after 11:30 a.m. on the same day until May 20, 2021. Ironwood focuses on developing treatments for gastrointestinal diseases, with linaclotide being a key product for IBS-C and CIC.
Ironwood Pharmaceuticals (NASDAQ: IRWD) will present at three major investor conferences in February and March 2021:
- SVB Leerink Global Healthcare Conference on February 26 at 8:00 a.m. EST
- Cowen Annual Health Care Conference on March 2 at 11:10 a.m. EST
- Barclays Global Healthcare Conference on March 9 at 3:35 p.m. EST
Investors can access live webcasts through the company's website, with replays available for 14 days after each conference. Ironwood specializes in GI-related healthcare, notably its leading treatment for IBS-C and CIC.
Ironwood Pharmaceuticals (Nasdaq: IRWD) announced its fourth quarter and full year 2020 results, highlighting significant growth in LINZESS net sales, which rose 10% year-over-year despite COVID-19 challenges. Total revenues for the fourth quarter were $116.7 million, down from $126.3 million in 2019, while full-year revenues decreased to $389.5 million from $428.4 million. Despite these declines, Ironwood reported a GAAP net income of $106.2 million for 2020, compared to $21.5 million in 2019. The company anticipates LINZESS net sales growth of 3-5% in 2021.
Ironwood Pharmaceuticals (Nasdaq: IRWD) announced that Mark Mallon will step down as CEO effective March 12, 2021, to pursue another opportunity. Thomas McCourt, currently president, will become interim CEO. Julie McHugh will serve as executive chair of the Board of Directors. The Board is initiating a search for Mallon's permanent successor. The company emphasizes its commitment to maximizing LINZESS, its leading product for GI diseases, and aims for sustained profitability and growth despite the ongoing challenges from the COVID-19 pandemic.
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced their fourth quarter and full year 2020 investor update conference call on February 17, 2021, at 8:30 a.m. Eastern Time. Participants can join via phone or access the webcast on their website. The call will also be available for replay starting the same day at 11:30 a.m. through March 3, 2021. Ironwood, founded in 1998 and headquartered in Boston, specializes in medicines for gastrointestinal (GI) diseases, including linaclotide, a leading treatment for IBS-C and CIC.
Ironwood Pharmaceuticals (NASDAQ: IRWD) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 5:20 p.m. ET. The presentation will include a corporate overview and a Q&A session. Interested parties can access a live webcast via Ironwood's website, with a replay available for 14 days post-conference. Ironwood specializes in developing treatments for gastrointestinal diseases, notably linaclotide for IBS-C and CIC, and was founded in 1998, based in Boston.